RxDoctor Payments Data

Sunny Goel, MD

Interventional Cardiology · Oceanside, NYNPI 1427498955

Payments from drug & device makers

$7,528in general payments, 2019–2025

Across 177 payments — averaging $42.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Medtronic$927
  • Boston Scientific$794
  • Shockwave Medical, Inc$632
  • Abiomed$532
  • E.r. Squibb & Sons, L.L.C.$285
  • plus $1K from 11 others

What the payments were for

  • Travel & lodging$1,23316%
  • Food & beverage$6,29584%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,528 in reported general payments places this provider in the 40th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$325,168
Medicare patients
441
Services billed
1,917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban123$143,396
EntrestoSacubitril/Valsartan67$64,966
FarxigaDapagliflozin Propanediol49$50,107
BrilintaTicagrelor42$39,566
Ranolazine ErRanolazine26$2,559
Atorvastatin Calcium152$2,069
Metoprolol Succinate137$1,849
Ezetimibe37$1,575
ClopidogrelClopidogrel Bisulfate122$1,527
Rosuvastatin Calcium50$828
Metoprolol Tartrate61$641
Pantoprazole Sodium48$457
Furosemide110$452
Spironolactone55$389
Losartan Potassium26$372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$279$64,96667 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Oceanside

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →